Sign inJoin waitlistJoin the waitlist

Gregory Biedermann

Interim Chair of Radiation Oncology · University of Missouri-Columbia School of Medicine

Credentials: · · · ·

History

Radiation Oncology Department · University of Missouri-Columbia School of Medicine
Present
University of Missouri-Columbia School of Medicine
Present

Boston University Medical Center
2002–2006
University of Virginia Medical Center
2001–2002
St Louis Univ Sch of Med
1997–2001

Research

Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy
International journal of radiation oncology · 2010 · 210 citations
Going Off Guidelines: An NCDB Analysis of Missed Adjuvant Therapy Among Surgically Treated Oral Cavity Cancer
Otolaryngology Head & Neck Surgery · 2023 · 14 citations
Implications of Treatment Modality on Chronic Opioid Use Following Treatment for Head and Neck Cancer
Otolaryngology Head & Neck Surgery · 2021 · Last of 8 authors · 11 citations

SL
Scott Litofsky
4 papers
Laura Dooley
3 papers
AC
Andrew Clark
2 papers · 2 as a resident
AW
Audrey Wallace
2 papers · 2 as a resident
Ayman Nada
2 papers
Craig Bollig
2 papers
DG
David Gilley
2 papers · 2 as a resident
JN
Jay Nelson
2 papers · 1 as a resident
JC
Joseph Cousins
2 papers
Michael Topf
2 papers
Patrick Tassone
2 papers
Paul Dale
2 papers

Clinical trials

Testing Less Intensive Radiation With Chemotherapy to Treat Low-risk Patients With HPV-positive Oropharyngeal Cancer
Principal investigator · Recruiting · Phase 2
University of Missouri-Columbia
2020–2026
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Site PI · Recruiting · Phase 3
NRG Oncology
2025–2035
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Site PI · Recruiting · Phase 2
NRG Oncology
2023–2033
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Site PI · Recruiting · Phase 3
NRG Oncology
2021–2041